Cartesian Therapeutics (RNAC) Invested Capital (2015 - 2026)

Cartesian Therapeutics (RNAC) has reported Invested Capital for 8 consecutive years, with $10.2 million the latest figure, recorded in Q2 2023.

• In Q2 2023, Invested Capital rose 211.57% year-over-year to $10.2 million; the TTM figure through Mar 2024 stood at $10.2 million (down 63.26% YoY), while the FY2022 annual figure was $8.5 million, up 42.19% from the prior year.
• Invested Capital held at $10.2 million in Q2 2023 per RNAC's latest filing, from $10.2 million in the prior quarter.
• Across five years, Invested Capital topped out at $21.5 million in Q2 2019 and bottomed at $460000.0 in Q1 2021.
• Historically, Invested Capital has averaged $10.0 million across 5 years, with a median of $8.4 million in 2020.
• Annual changes were most pronounced in 2021 — Invested Capital plunged 97.27% — and 2023, when it soared 1368.1%.
• Cartesian Therapeutics' Invested Capital stood at $18.9 million in 2019, then slumped by 55.65% to $8.4 million in 2020, then decreased by 28.9% to $6.0 million in 2021, then jumped by 42.19% to $8.5 million in 2022, then gained by 20.75% to $10.2 million in 2023.
• Business Quant data shows RNAC's Invested Capital at $10.2 million in Q2 2023, $10.2 million in Q1 2023, and $8.5 million in Q4 2022.